INmune Bio, Inc.
INMBNASDAQ
Healthcare
Biotechnology
$1.21
-0.02(-1.6%)
52W $1.12 – $8.24
Deepening losses reflect clinical-stage investments amid revenue emergence from CORDStrom sales, with operating cash burn halved through efficiency gains while net losses widened due to higher G&A from stock compensation.
$32MMkt Cap
$50.0KRev TTM
-$50MNI TTM
-0.7xP/E TTM
Latest Earnings
10-K
FY FY2025Mar 29, 2026Deepening losses reflect clinical-stage investments amid revenue emergence from CORDStrom sales, with operating cash burn halved through efficiency gains while net losses widened due to higher G&A from stock compensation.
What Changed Recently
Fundamentals
How The Business Makes Money
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.
Industry Biotechnology
Company Profile
CIK0001711754
ISINUS45782T1051
CUSIP45782T105
Phone858 964 3720
Address225 NE Mizner Boulevard, Boca Raton, FL, 33432, US
SEC EDGAR